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Abstract Granulocyte-macrophage colony-stimulating factor
(GM-CSF) is a cytokine involved in haematopoiesis and host
defence. Production of GM-CSF has been detected in tumour
cells including the U87MG astrocytoma cell line. Previous
studies have been focused on the regulatory role of the proximal
region of the GM-CSF promoter. Our studies on the distal
region of the promoter in U87MG cells identify a negative cis
element (31377/31298) which contains a AP1-like site able to
bind c-jun and c-fos transcription factors, according to the results
of DNA/protein binding assays. Mutagenesis of the AP1-like site
eliminates AP1 binding and the negative effect on promoter
activity.
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1. Introduction
Granulocyte-macrophage colony-stimulating factor (GM-
CSF), a glycoprotein cytokine involved in haematopoiesis
and host defence, can be produced by di¡erent cell types in
response to appropriate stimuli. Constitutive expression of
GM-CSF has been detected in acute myeloid leukaemia, sol-
id-tumour cells and several cell lines [1], including the U87MG
astrocytoma cell line [2].
GM-CSF production is highly controlled both at the tran-
scriptional and at the post-transcriptional level [1]. Transcrip-
tional control is regulated by di¡erent transcription factors
whose binding sites have been identi¢ed in the most proximal
(629 bp) promoter region. In addition, a strong cyclosporin
A-sensitive enhancer, located 3 kb upstream of the GM-CSF
transcriptional start site, was previously described [3]. We
previously identi¢ed a NF-UB-like binding site, located be-
tween 32002 and 31984, acting as a positive transcriptional
element in the Mo lymphoblastoid cell line [4]. This same NF-
UB-like binding site participates in response to phorbol ester
in 5637 cells derived from bladder carcinoma [5]. These ob-
servations suggested that important regulatory elements in
distal regions of the GM-CSF promoter may signi¢cantly
contribute to the transcriptional regulation of the gene, in
physiological and/or pathological conditions, as well as in a
tissue-speci¢c way. In order to continue our investigation on
distal promoter elements, we have performed transfection ex-
periments in U87MG cells, derived from the astrocytic cell
lineage and expressing GM-CSF. We found a negative regu-
latory cis element (between 31377 and 31298 bp), which
contains an AP1-like site. The products of the proto-onco-
genes c-jun and c-fos, members of the AP1 transcription factor
family, are leucine zipper proteins able to bind the TPA-re-
sponsive element (TRE) TGA(C/G)TCA as Jun/Jun homo-
dimers or Jun/Fos heterodimers.
We report here that the AP1-like site (TGAATCA) in the
GM-CSF promoter is able to bind c-jun and c-fos transcrip-
tion factors. The substitution of the ¢rst nucleotide (T to G)
of the core consensus sequence in the above AP1-like site
eliminates both the c-jun and c-fos binding and the negative
regulatory e¡ect on promoter activity.
2. Materials and methods
2.1. Cell culture and transient transfections
Cell lines (U87MG, 5637 and HeLa) were cultured in DMEM
(Dulbecco’s modi¢ed Eagle’s medium) supplemented with 10% foetal
calf serum, 2 mM glutamine and 0.05 mg/ml gentamicin.
Transfections of U87MG cells were performed by the standard
calcium phosphate coprecipitation technique [6] using 10 Wg of plas-
mid pPF20 and equimolar amounts of the other constructs, together
with 800 ng of pCMV-L-galactosidase as internal control. Chloram-
phenicol acetyltransferase (CAT) activity was measured by standard
methods [7] after normalising for L-galactosidase activity and protein
concentration. All experiments were performed in duplicate.
2.2. GM-CSF mRNA and protein assay
Total cellular RNA was puri¢ed according to Chomczynski and
Sacchi [8]. RT-PCR was performed as described [9] and the RT-
PCR assay of GAPDH mRNA was included in all tested samples
as a control.
Assay of GM-CSF protein in cellular conditioned medium was
performed by a solid-phase immunoenzymetric assay (EASIA, Med-
genix Diagnostics, Fleurus, Belgium) as previously described [10].
2.3. Nuclear extracts and DNase I footprinting
Nuclear extracts from 5637 cells, HeLa cells, both stimulated with
50 ng/ml TPA for 8 h, and U87MG cells were prepared according to
the method of Dignam et al. [11] and dialysed against a bu¡er con-
taining 25 mM HEPES, pH 7.9, 100 mM NaCl, 0.2 mM EDTA, 0.5
mM dithiothreitol, 0.5 mM phenylmethylsulphonyl £uoride and 10%
glycerol. A 3P end-labelled 224 bp footprinting probe, which includes
the 151 bp promoter region from 31416 to 31266, was prepared by
cleaving plasmid pCla3 (see Section 2.5) with HindIII, labelling at the
3P end with Klenow enzyme and a dNTP mixture containing
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[K-32P]dCTP, digesting with EcoRI and purifying the end-labelled
DNA fragment on a 5% polyacrylamide gel. The DNA binding reac-
tion was performed in a ¢nal volume of 50 Wl containing 25 mM
HEPES, pH 7.9, 0.1 mM EDTA, 0.5 mM dithiothreitol, 0.1 M
NaCl, 10% glycerol, 2 Wg of [poly(dI-dC)], 25 fmol of end-labelled
DNA probe and increasing amounts (15, 22.5, 30, 37.5 Wg) of nuclear
extract or bu¡er used for dialysis of nuclear extracts. The binding
reaction was allowed to proceed at room temperature for 20 min.
DNase I (Boehringer, grade I, 1 mg/ml in 50% glycerol) was appro-
priately diluted (1:100 for samples containing nuclear extract and
1:1000 for samples without extract) immediately before use in an
ice-cold bu¡er containing 10 mM Tris-HCl (pH 7.5), 50 mM NaCl,
62.5 mM MgCl2, 10 mM CaCl2 and 1 mg/ml bovine serum albumin.
2 Wl was added to the binding mixture and incubated for 1 min (samples
with extract) or 30 s (samples without extract) at room temperature.
The reaction was stopped with 15 Wl of 5% SDS, 125 mM EDTA and
0.7 mg/ml tRNA, and the samples subjected to phenol-chloroform
extraction and ethanol precipitation. The digestion products were
then analysed by electrophoresis on denaturing 8% polyacrylamide
gel containing 7 M urea. An aliquot of the same end-labelled DNA
fragment was also subjected to the G+A sequencing reaction [12] and
loaded on the same gel for identi¢cation of protected sequences.
2.4. Electrophoretic mobility shift assay (EMSA)
Blunt-ended double-stranded oligonucleotides corresponding to the
GM-CSF promoter wild-type sequence between 31312 and 31293
(RI) 5P-TTTAGGCTGAATCAGCCTCT-3P (upper strand) and mu-
tant sequence (mRI) 5P-TTTAGGCGGAATCAGCCTCT-3P (upper
strand) were used as labelled probes or as unlabelled competitors.
Double-stranded oligonucleotide described to bind selectively AP1
(TRE) 5P-GCGCGCTTGATGACTCAGCCGGAA-3P (upper strand)
and 5P-GCGTTCCGGCTGAGTCATCAAGCG-3P (lower strand),
blunt-ended double-stranded oligonucleotides described to bind NF-
UB 5P-GTAGGGGACTTTCCGAGCTCGAGATCCTATG-3P (upper
strand) and E2F 5P-TAGTTTTCGCGCTTAAATTTGA-3P (upper
strand) were also used. The oligonucleotides were labelled with T4-
polynucleotide kinase and [Q-32P]ATP. The labelled fragments were
incubated with 4 Wg/assay of non-speci¢c DNA [poly(dI-dC)], in
12.5 mM HEPES, pH 7.9, 50 mM NaCl, 0.5 mM phenylmethylsul-
phonyl £uoride, 0.5 mM dithiothreitol and 10% glycerol. Nuclear
extract (6.5 Wg protein/assay) were added to a total volume of 15 Wl
and the reaction incubated at room temperature for 20 min. Reaction
products were resolved on a 5% polyacrylamide gel in 0.25UTBE (22
mM Tris borate, 0.25 mM EDTA). Gels were dried prior to auto-
radiography at 370‡C. Anti-c-jun (Santa Cruz Biotechnology) and
anti-c-fos (Oncogene Science) polyclonal antibodies were used to
test for the presence of c-jun and c-fos in the gel shift complex. The
antibodies were pre-incubated with nuclear extract and [poly(dI-dC)]
for 15 min at 50 ng, 100 ng, 200 ng for anti-c-jun and 100 ng, 250 ng
for anti-c-fos before the addition of the labelled oligonucleotide in the
EMSA binding mixture; the mixture was then incubated for an addi-
tional 15 min at room temperature before gel electrophoresis.
2.5. Plasmid construction and mutagenesis
Plasmid pPF2000 [13], which contains the ¢rst 2010 bp upstream of
the transcription start site, was used to create, by means of PCR,
constructs containing the RI element. The pair of oligonucleotides
RI-1 5P-GCAGACTCAGACCACAGTGC-3P, corresponding to the
sequence located between 31416 and 31397 in the 2010 bp GM-
CSF promoter, and RI-2 5P-ACTCCAGGTGCAGTGCCTCT-3P,
corresponding to the 31285 to 31266 sequence, were used to generate
a PCR product containing the GM-CSF promoter sequence located
between 31416 and 31266. In order to facilitate the subsequent clon-
ing into the pBLCAT2 vector, BamHI restriction sites were intro-
duced at the 5P end of oligonucleotides RI-1 and RI-2. The PCR
fragment was digested with BamHI and subcloned in the polylinker
of the pBLCAT2 vector, upstream of the thymidine kinase promoter
(pCla3).
Site-directed mutagenesis of pPF22 (starting at nucleotide 1377 up-
stream of the transcription start site) was performed using a two-step
PCR procedure with a set of four primers (RI-3, RI-4, E1 and E2), as
previously described [14]. Primers RI-3 and RI-4 correspond to the
double-stranded mutant oligonucleotide mRI, while primer E2 5P-
CTCCCGGAACGACCCCTTCG-3P corresponds to the promoter se-
quence between 3881 and 3862, and E1 5P-GGTGCGGGCCTCTT-
CGCTAT-3P corresponds to a sequence of pBLCAT3 vector (281^
300). We obtained a 670 bp product with a substitution in the ¢rst
nucleotide (31305) of the AP1-like site (GGAATCA). This PCR
product (including 516 bp promoter from 31377 to 3862 and 154
bp of the pBLCAT3 vector) produced, by digestion with NsiI and
BamHI, a fragment of 197 bp that was reinserted in the pPF22 sub-
stituting the wild-type fragment (pCla22).
3. Results and discussion
3.1. GM-CSF mRNA expression in U87MG cells
Our preliminary RT-PCR assay of the basal amount of
GM-CSF mRNA in U87MG cells showed an undetectable
mRNA level compared with the high mRNA level expressed
by Mo cells (data not shown). On the other hand, the EASIA
GM-CSF protein assay of U87MG cell cultures conditioned
medium showed synthesis of about 40 pg/ml, compared with
2000 pg/ml in conditioned medium of the T lymphoid Mo cell
line. Taken together, these results con¢rm that U87MG shows
constitutive GM-CSF expression although at a low level, as
previously reported [2] ; therefore U87MG cells represent a
useful model to continue our investigation of transcriptional
regulation of this cytokine in di¡erent GM-CSF-producing
cellular systems.
3.2. Functional analysis of GM-CSF promoter sequences in
U87MG cells
The plasmid PF2000, containing the fragment of the GM-
CSF promoter from 32010 to +26 fused to the CAT reporter
gene and di¡erent plasmids containing progressive deletions
of the above promoter region (PF20, PF22, PF18, PF12,
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Fig. 1. Functional activity of the GM-CSF promoter constructs in U87MG cells. Values represent the mean þ S.E.M. of CAT activity of at
least three independent experiments performed in duplicate. CAT activity of pPF24 is considered 100%.
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PF14, PF4, PF24), as previously described [13], were used in
transient transfection experiments in U87MG cells. Fig. 1
shows the results of transfection experiments referred to pro-
moter activity of the pPF24 (3240 to +26 promoter fragment)
considered as 100%. We observed the highest promoter activ-
ity with the promoter sequence contained in pPF24 and a
general repression with the upstream sequence up to 32010.
Transfections with intermediate constructs indicated a de-
crease of activity between pPF2000 (32010/+26) and pPF20/
pPF22 (31742/+26; 31377/+26) and a signi¢cant increase of
activity with pPF10 (31298/+26). This con¢rmed that the
previously described positive element between 32002 and
31984 [5,6] was e¡ective also in this cell type and suggested
the presence of negative regulatory elements.
3.3. The GM-CSF promoter sequence between 31416 and
31266 is recognised by nuclear factors
A restriction fragment containing the 151 bp promoter se-
quence between 31416 and 31266 was used as a labelled
probe for footprinting analysis with a nuclear extract from
U87MG cells, to identify DNA/protein binding sites in the
above negative regulatory element. Our results show a hyper-
sensitive site located around 31333, as well as an area of
relative protection between 31312 and 31293 (Fig. 2).
A computer analysis of the protected sequence (RI) indi-
cated a potential AP1-like site (TGAATCA) and an upstream
partially overlapping E2F-like binding site (TTTAGGCTG).
To further characterise the trans-acting factors binding to the
above described sequence, we synthesised a double-stranded
oligonucleotide reproducing the 31312 to 31293 sequence
(RI) that corresponds to the DNase I protected region. An
EMSA assay with nuclear extract of U87MG cells resulted in
the appearance of two retarded complexes, as shown in Fig.
3a, lane 1. Complex I was speci¢cally competed in a dose-
dependent manner by the same unlabelled oligonucleotide
used as a probe (lanes 2, 3, 4), whereas complex II, which
was not competed, was due to non-speci¢c binding. This
was also con¢rmed in EMSA assays when [poly(dI-dC)] was
pre-incubated with nuclear extract resulting in the disappear-
ance of complex II (data not shown). Competition with dou-
ble-stranded oligonucleotides containing AP1, E2F and NF-
UB binding sites indicated that the AP1 oligonucleotide was
able to compete complex I formation as e⁄ciently as the RI
oligonucleotide (lanes 8, 9, 10), whereas the E2F oligonucleo-
tide was a very weak competitor (lanes 5, 6, 7) and NF-UB
was unable to compete (data not shown). Complex II was not
competed by any of the above oligonucleotides.
3.4. AP1 family members binding to the RI element
When we used the AP1 oligonucleotide as a labelled probe
in comparison with the RI oligonucleotide (Fig. 3b) we ob-
served that the retarded complexes were identical (lanes 1, 3)
and complex I was competed by the RI oligonucleotide (lane
2). Moreover, complex I was abundantly present in nuclear
extracts from the 5637 and HeLa cell lines both induced with
TPA (lanes 4, 5).
The above results strongly suggest that an AP1 factor binds
the RI oligonucleotide and, therefore, we used speci¢c anti-c-
jun and anti-c-fos antibodies in EMSA assays to further sup-
port this hypothesis (Fig. 4). When we used the RI oligonu-
cleotide as a labelled probe and the antibodies were pre-incu-
bated with nuclear extract and the [poly(dI-dC)] non-speci¢c
competitor, we observed that complex I was signi¢cantly re-
duced with anti-c-jun antibody in a dose-dependent manner
(Fig. 4a, lanes 3^5). The same e¡ect, although less striking,
was observed with the anti-c-fos antibody (Fig. 4b). When we
used an AP1 consensus oligonucleotide as a labelled probe, we
obtained reduction of complex I with both antibodies (Fig.
4c). These results indicate that c-jun and c-fos proteins are
components of complex I.
3.5. E¡ect of mutagenesis on AP1 binding and on promoter
activity
We then synthesised a double-stranded mutant oligonucleo-
tide containing a single base substitution (T to G) on the basis
of previous data about the bases required for AP1 binding
[15]. This mutant oligonucleotide (mRI) was unable to com-
pete binding of complex I (Fig. 5a, lane 3) and, when used as
a labelled probe, was unable to form the complex (lanes 4, 5,
6).
The same single base pair mutation that abolished the bind-
ing of complex I in EMSA was introduced in a construct
containing a promoter fragment from 31377 to +26
(pCla22) that was used in transient transfection experiments
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Fig. 2. DNase I footprinting of the GM-CSF promoter sequence be-
tween 31416 and 31266. Lane 1, G+A sequence; lane 2, without
extract; lanes 3^6, with 15, 22.5, 30, 37.5 Wg of U87MG crude nu-
clear extract, respectively. The arrow indicates the hypersensitive
site, the bar indicates the protected region.
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in comparison with its wild-type counterpart pPF22. Muta-
genesis resulted in an increase of promoter activity that was
comparable to the activity of a construct (pPF10) in which the
negative element was deleted (Fig. 5b). Therefore the negative
e¡ect on transcription of the RI element can be suppressed by
deletion or by targeted mutation in the AP1-like sequence.
Cytokine expression in the central nervous system has been
mainly referred to the role of regulation of the immune re-
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Fig. 3. Electrophoretic mobility shift assays with the RI and AP1 probes. a: The labelled RI oligonucleotide was incubated with 6.5 Wg of
U87MG nuclear extract: without competitor (lane 1); competition with 100-, 200-, 400-fold molar excess of unlabelled RI oligonucleotide (lanes
2^4) or the same amounts of unlabelled E2F oligonucleotide (lanes 5^7) or of unlabelled AP1 oligonucleotide (lanes 8^10). b: RI and AP1 oli-
gonucleotides were both used as labelled probes as indicated, RI oligonucleotide was used as competitor (400-fold molar excess, lane 2). Nu-
clear extracts were from U87MG cells (lanes 1^3), TPA-induced (50 ng/ml for 8 h) 5637 cells (lane 4) and HeLa cells (lane 5). I and II indicate
retarded complexes.
Fig. 4. Electrophoretic mobility shift assays with nuclear extracts from U87MG cells in the presence of anti-c-jun and anti-c-fos antibodies. a:
The assay was performed with RI oligonucleotide as labelled probe in the presence of pre-immune serum (lane 1) or in the presence of 50 ng
(lane 3), 100 ng (lanes 4, 6), 200 ng (lane 5) of anti-c-jun antibody. A 400-fold molar excess of RI unlabelled oligonucleotide as competitor was
included in lanes 2 and 6. b: Assay performed with RI oligonucleotide as labelled probe in the presence of pre-immune serum (lane 1), or in
the presence of 100 ng (lane 2) and 250 ng (lane 3) of anti-c-fos antibody. c: Assay performed with AP1 oligonucleotide as labelled probe in
the presence of pre-immune serum (lane 1), in the presence of 100 ng of anti-c-jun antibody (lane 2), 100 ng (lane 3) and 250 ng (lane 4) of
anti-c-fos antibody.
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sponse, but increasing evidence suggests that some of them,
among which GM-CSF, also play an important role in estab-
lishing and maintaining the normal homeostatic environment,
besides functioning as intercellular signals that orchestrate the
response to injury. GM-CSF, locally produced by glial astro-
cytes, provides an essential element for recruitment and acti-
vation of blood-derived monocytes as well as resident brain
macrophages. Furthermore, GM-CSF seems to be required
for survival and function of microglia since it is able to en-
hance microglial survival and it is the most e¡ective stimulus
promoting morphological di¡erentiation in foetal cultures
[16]. The immunocytochemical localisation of GM-CSF, re-
stricted to reactive astrocytes, has been demonstrated in the
characteristic lesions of multiple sclerosis and Alzheimer’s dis-
ease [16].
AP1 was originally described as a transcriptional activator
of several genes, induced as part of the cellular immediate
early response to serum stimulation or to phorbol esters
[17]. However, AP1 has also been reported to behave as a
negative trans-acting factor of various genes including c-fos,
osteocalcin, insulin, adipocyte P2, muscle creatine kinase and
Myo D [18]. The way by which this negative e¡ect is achieved
is not homogeneous and therefore di¡erent molecular mech-
anisms have to be considered. For example, muscle creatine
kinase transcription is repressed by AP1 through inhibition of
the muscle-speci¢c transactivators myogenin and Myo D
mediated by their interaction with c-jun and subsequent pre-
vention of DNA binding [19,20]. Repression of the c-fos pro-
moter results from direct binding to a TRE element [21] and a
similar mechanism seems to be active also on the MHC class I
gene [18]. More complex interactions have been described for
insulin [22], rat prolactin [23], osteocalcin [24], atrial natriu-
retic factor [25] and chorionic gonadotrophin K and L [26]
promoters. The GM-CSF promoter contains a sequence,
named hCLEO, located between 354 and 330, which is a
binding site for AP1 in cooperation with other factors such
as Elf-1, NF-ATp and NK-UB [27,28]. A similar site, in which
AP1 and NF-AT interact in a cooperative fashion, is also
present within the cyclosporin A-sensitive enhancer, located
3 kb upstream of the GM-CSF gene [3]. Both these sites act
as positive elements in GM-CSF regulation.
The expression of cytokines is tightly controlled in the pro-
ducing cells with transcriptional initiation starting only after
proper stimulation and with several positively and negatively
acting factors involved in a concerted regulation at multiple
sites of cytokine promoters. Negative regulatory elements and
cognate trans-acting factors have been identi¢ed in most cy-
tokine promoters [29]. Regarding GM-CSF, negatively acting
elements have been found in a region containing three copies
of the CATT sequence between 365 and 331 [30] and in the
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Fig. 5. a: Electrophoretic mobility shift assays with the mutant RI probe (mRI). RI and mRI oligonucleotides were used as labelled probes or
unlabelled competitors (400-fold molar excess) as indicated. In all assays nuclear extract from U87MG cells was used. b: E¡ect of mutagenesis
on promoter activity. Functional analysis of the construct (pCla22) containing the T to G mutation at the AP1-like site in comparison with the
activity of the wild-type construct (pPF22) and of the construct in which the negative element was deleted (pPF10). Values represent the
mean þ S.E.M. of CAT activity of at least three independent experiments performed in duplicate. The activities of pCla22 and pPF10 were re-
lated to the activity of pPF22, set at 100%.
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region containing the CK1 and CK2 elements between 3114
and 366 [31]. Our results indicate that another more up-
stream region contains a negative regulatory sequence that
interacts with an AP1 factor.
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